PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Completed · Early Phase 1 · Has a placebo group
Conditions studied: Focal Segmental Glomerulosclerosis
In brief
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Key facts
- Study ID
- NCT03763643
- Run by
- University of Minnesota
- People needed
- 21
- Starts
- 2019-07-01
- Expected to finish
- 2025-02-07
- Last updated by the study team
- 2025-09-10
Who can join
Age: 1 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama — Tuscaloosa, Alabama, United States
- University of California at Davis — Davis, California, United States
- Lurie Children's Hospital — Chicago, Illinois, United States
- University of Iowa — Iowa City, Iowa, United States
- Children's Hospital of Colorado — Aurora, Minnesota, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Duke University — Durham, North Carolina, United States
- University of Cincinnati — Cincinnati, Ohio, United States
- Cincinnati Children's Hospital — Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.